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Abstract 
 
Objective 
 
To estimate the surveillance incidence of first time diagnosis of Narrow Phenotype Bipolar I 
Disorder (NPBDI) in young people under 16 years by Consultants in Child and Adolescent 
Psychiatry (CCAP) in the British Isles and describe symptoms, co-morbidity, associated 
factors, management strategies and clinical outcomes at 1-year follow up. 
 
Method 
 
Active prospective surveillance epidemiology was utilised to ask 730 CCAP to report cases 
of NPBDI using the Child and Adolescent Psychiatry Surveillance System (CAPSS). 
 
Results 
Of the 151 cases of NPBDI reported, 33 (age range 10-15.11 years) met the DSM-IV 
analytical case definition with 60% having had previously undiagnosed mood episodes. The 
minimum 12 month incidence of NPBDI in the British Isles was 0.59/100,000 (95% CI 0.41 
- 0.84). Irritability was reported in 72% cases and co-morbid conditions in 51.5% cases with 
48.5% cases requiring admission to hospital. Relapses occurred in 56.67% cases during the 
one year follow up. 
 
Conclusions 
These rates suggest that the first time diagnosis of NPBDI in young people less than 16 
years of age by CCAP in the British Isles is infrequent; however, the rates of relapse and 
admission to hospital warrant close monitoring.  
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Significant Outcomes 
 
The early age at onset of NPDBI, high rates of inpatient treatment, and significant relapse 
rates highlight the need for early and accurate diagnosis, and careful follow up by child 
and adolescent mental health services. 
 
 
 
 
Limitations 
 
Surveillance epidemiology relied on a single information source: CCAPs to report cases 
and then complete questionnaires which cannot be guaranteed to be comprehensive.  
The authors were aware that data were unavailable for 25 (of 151) young people due to 
loss to follow up after initial notification by CCAP. 
Cases not within Child and Adolescent Mental Health Services would not have been 
reported. 
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Introduction 
 
In his original seminal papers, that differentiated Bipolar Disorder (BD) from schizophrenia, 
Emil Kraeplin described Paediatric Bipolar Disorder (PBD) as a rare condition (1). Studies 
have focussed on the epidemiology of PBD with a recent meta-analysis reporting the rate 
as 1.1% (2); and included studies that included subjects up to the age of 21 years. Most 
studies have focussed on the prevalence of PBD which has been reported to vary from 0.1% 
to 2% (3)(4)(5)(6)(7). In their UK cross-sectional national survey of a sample (N=5326) of 8-
19 year olds from the general population using information from parents and youth, 
Stringaris and colleagues reported that only 7 of 5326 (0.1%) children and youth aged 8 to 
19 years met the threshold for a probable or definite diagnosis of Bipolar I (BDI) or Bipolar 
II (BDII) Disorder (8) when assessed by the Developmental and Well-Being Assessments 
(DAWBA). In their study the prevalence for a diagnosis of Bipolar Disorder Not Otherwise 
Specified (BDNOS) was 10 fold higher than that for BDI or BDII in this study. The instruments 
used to ascertain symptomatology were robust but the study design could not answer the 
question of how frequently PBD was diagnosed in routine clinical care across the British 
Isles. In a UK clinic-based study, Chan and colleagues reported 1% (n=35) of 3586young 
people under 18 years seen in a large NHS mental health trust received a diagnosis of PBD 
between 1992 and 2007 (9). Furthermore, the authors reported that only 0.3% of the clinic 
sample that received a diagnosis of PBD was under the age of 13 years with the youngest 
subject being 7 years of age. This study had trainee or Consultants in Child and Adolescent 
Psychiatry (CCAP) and clinical psychologists complete ‘item sheets’ to collect demographic 
and symptom characteristics. The inter-rater reliability of the item sheets ranged from 0.61-
0.94 and the accuracy of identifying items definitely present or not was greater than 95% 
(10). In addition although this study described the associated features seen in the cases of 
PBD, however, it too did not use a national case ascertainment strategy.  
 
Few studies have attempted to study the incidence of PBD. Post and colleagues (11) 
assessed the incidence of PBD in the USA and Europe in a cohort of 500 outpatients (mean 
age 42 years) using structured interviews and questionnaires about the nature and course 
of their illness. Adolescent onset of symptoms was reported in 61% of the American cohort 
of adults with BD compared with 30% of the European (Dutch and German) cohort. 
Childhood-onset was reported in 2% of the European cohort compared with 22% in the 
American cohort. The study was limited by its retrospective nature as well as the lack of 
clinical assessments at the time of onset of symptoms. The only other study that has 
attempted to estimate incidence of BD (BDI and BDII) across the life span was a cohort 
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study conducted in the Netherlands using data from a general practitioners research 
database with a longitudinal electronic record of 800000 patients (12). The study reported 
an overall incidence of BD as 7/100 000 (95% CI: 5.7-8.3); the incidence of BDI as 4.3/100 
000 (95% CI: 3.4-5.5) and the incidence of BDII as 1.9/100 000 (95% CI: 1.3-2.7). 
Interestingly the study identified 2 peaks in the age at onset of the disorder: one in early 
adulthood (15-24 years; 6.8/100 000) and a larger peak in later life (45-54 years; 12/100 
000). A recent meta-analysis has attempted to characterise the clinical characteristics of 
PBD and reported considerable heterogeneity (13). One of the reasons for this 
heterogeneity and the varying epidemiological rates for diagnosis is that studies do not 
always differentiate the narrow (14) from the broad (15) phenotypes for PBD. The narrow 
phenotype is defined as a symptom profile that meets the full DSM-IV (16) diagnostic criteria 
for hypomania or mania, has the hallmark symptom of elevated mood and meets the 
duration criterion whereas for the broader phenotype the mood disturbance could be 
elevation and/or irritability of mood. In addition The diagnosis of PBD in the British Isles 
remains a source of controversy with multiple issues that potentially make the diagnosis 
difficult. The first is whether and how frequently manifestations of mania and sub-syndromal 
mania are present in preadolescents (17, 18). The second factor is whether there are any 
differences in clinical manifestations of BD by age (19, 20) and whether there should be 
modifications of the criteria required for diagnosis such as the numbers of symptoms for age 
as has been suggested for depression (21). Some researchers in the field refer to a category 
of preadolescent/prepubertal subtype of PBD suggesting that subjects in this subtype may 
perhaps manifest the condition differently from adults. These researchers report that the 
subjects with this subtype have PBD characterised by less discrete episodes and greater 
irritability and volatility (22, 23). Other studies suggest that subjects with this subtype of PBD 
have more mixed episodes with less complete remissions and more mood shifts compared 
to adults (24, 25). A third factor is whether developmental modifications should be made for 
the definition of the symptoms of mania (26). For example, grandiosity is a core feature of 
mania across the life cycle but the specific behaviours that a subject with PBD might display 
may well be different from an adult subject with BD perhaps as a consequence of differences 
in setting, opportunity, experience and development (27). The fourth issue is whether 
comorbidities vary as a function of chronological and developmental age (28). Data from the 
USA suggests that children with mania often also meet criteria for ADHD thereby posing the 
question whether the apparent comorbidity is a function of the base rate of ADHD (29, 30) 
versus reflecting shared symptoms (31) or perhaps a developmental subtype of BD (32). 
The fifth issue is about how to define the mood disturbance that is an essential part of 
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mania/hypomania. DSM-IV states that either elevation/irritability can be a core symptom but 
the UK NICE guidelines (33) and the USA National Institute of Health (NIH) group (14) have 
recommended that elevation of mood alone should be used for the diagnosis of PBD. The 
last issue is around the minimum duration of symptoms required for the definition of a mood 
episode. Data from the USA suggests that a significant number of cases of PBD present as 
BD NOS- that is having the same symptoms for a manic episode but of much shorter 
duration such as lasting a few hours (usually >4 hours) to days (25, 34). Given these issues, 
our research team made a decision to use the DSM-IV criteria for BDI as modified by the 
NICE guidelines to study a less heterogenous but well recognised group of Narrow 
Phenotype Bipolar I Disorder (NPBDI) wherein a case could be diagnosed only if they had 
elevated mood (irritability on its own was not considered a core diagnostic feature) and the 
symptoms had to be present for at least 7 days (or less if the case required admission to 
hospital). 
 
Data on the epidemiology of PBD and co-morbid conditions are important for healthcare 
planning. There are no published data from the UK on the incidence of PBD. Furthermore, 
there are limited UK data on co-morbid conditions seen in subjects with PBD (9). Data from 
the USA indicates high levels of co-morbid conditions including neurodevelopmental 
disorders such as Attention Deficit Hyperactivity Disorder (ADHD) (30)(29) and Autism 
Spectrum Disorder (ASD) (35) as well as additional mental health disorders such as anxiety 
disorders (36)(37)(38). The authors developed this study to use active prospective 
surveillance methodology which is an internationally accepted research technique to assess 
epidemiology of rare disorders (39-41).  A decision was made to ask CCAP to report cases 
under 16 years of age. This was based on the fact that firstly, at the time of the study, some 
CCAP in the British Isles only saw patients up to the age of 16 years. This would have meant 
that not all 17 year olds would have had a chance to be reported making the denominator 
in the calculation of incidence difficult if all those under 18 were measured. Secondly, the 
Child and Adolescent Psychiatry Surveillance System (CAPSS) recommended that in light 
of the peak age of onset of NPBDI being 15-19 years (42), the research team restrict the 
age under study to less than 16 years, to reduce the burden of reporting cases on CCAP. 
Aims of the study 
To estimate the surveillance incidence of first time diagnosis of NPBDI in young people 
under 16 years by CCAP in the British Isles. Furthermore, the study aimed to describe 
symptoms, co-morbidity, associated factors, management strategies and clinical outcomes 
at 1-year follow up. 
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Materials and Method 
The CAPSS mailed a yellow reporting card every month from September 2009 until September 
2010 to the 730 CCAP in the United Kingdom (UK) and the Republic Of Ireland (ROI) asking 
them to report all new cases of NPBDI they had diagnosed in the past month or importantly to 
indicate that they had nothing to report. The yellow cards were returned to CAPSS at the Royal 
College of Psychiatrists, in London, UK who notified the research team of positive case reports. 
The study team then sent a brief Initial Questionnaire (13 items) (version 4.7; online 
supplement XXX) to the CCAP who had reported the case. For the cases that met the analytical 
case definition (described below), the reporting CCAP received a Follow up Questionnaire (11 
item) (version 4.7; online supplement XXX), 1 year after the initial case report. These 
questionnaires had been developed in collaboration with service users, researchers at 
Newcastle and Oxford Universities and CAPSS and had been piloted among CCAPs in the 
North East of England.  
 
Surveillance epidemiology requires a broad surveillance case definition to encourage reporting 
of all probable cases in the age range being studied with a more restrictive analytical case 
definition to confirm ‘caseness'. The surveillance case definition for a case of NPBDI was 
based on the DSM-IV criteria (16) for BD modified by the National Institute for Health and 
Care Excellence (NICE) Guidelines for BD (33). The surveillance case definition for NPBDI 
was designed to encourage over reporting of cases rather than under reporting. This 
surveillance case definition was a disturbance of mood characterised by ONE episode of 
euphoric or expansive mood, (this might include irritability) present for at least 7 days (less if 
hospitalised) that is sufficiently severe to cause impairment in social functioning. The specific 
instructions to CCAPs were: ‘Please report any child, younger than 16 years of age receiving 
a first time diagnosis of BD and presenting in the previous month with at least one 7 day 
period (less if hospitalised) of abnormally and persistently elevated or expansive and 
possibly irritable mood consistent with BD. Exclude cases where the disturbance in mood is 
due to a direct physiological consequence of a) a general medical condition e.g. 
hyperthyroidism OR b) a drug of abuse, a medication, another somatic treatment of 
depression e.g. light therapy or toxin exposure’. 
 
Potential cases were then confirmed using the analytical case definition from data provided by 
responses on the initial questionnaire. A panel consisting of 2 child psychiatrists (AS and NC) 
and the study coordinator (JN) reviewed all available clinical information from the initial 
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questionnaires to achieve best estimate clinical diagnosis. The study methodology, case 
definitions and questionnaires were approved by the CAPSS executive committee and the 
NHS Research Ethics system (Charing Cross REC (09\H0711\28). National Information 
Governance Board Section (NIGB) 251 support was also obtained to allow for notification of a 
case and collection of minimal patient identifiable data without the need for consent from the 
young person and their parent/carer (NIGB 2-06(g) 2009). NIGB support prevented 
duplication of cases (if the same case was reported by different CCAPs). 
 
Analyses 
Analyses were primarily descriptive using SPSS version 19 on Windows. Where cases were 
reported by 2 different CCAPs (duplicate cases) the study group only counted it as one case 
by using the questionnaire with the most complete dataset. Incidence was calculated as 
number of cases in the population (United Kingdom (UK) and Republic of Ireland (ROI)) 
expressed as per 100,000, using data for the total population of young people for 2009 aged 
10-16 years obtained from the Office of National Statistics (UK) and the Central Statistics 
Office (ROI). 
 
Results 
 
Mean monthly reporting yellow card response rate over the 13 month study period was 63% 
(range 59-72%). Figure 1 shows the flow diagram of case reporting. 
 
Figure 1 about here. 
 
Incidence 
 
Notification and subsequent confirmation of 33 cases of NPBDI during the study period 
provided an overall incidence rate estimate of 0.59 per 100,000 (95% CI 0.41 - 0.84). 
 
Demographics and type of index episode 
 
Of the 33 confirmed cases, 15 (45%) were male and 18 (55%) were female.  The index 
episode was manic in 24 of 33 confirmed cases (73%) in comparison with 9 cases (27%) 
presenting in a mixed episode. Twice as many female patients as male patients (M:F::3:6) 
presented in a mixed episode. 
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The median duration between first onset of symptoms and diagnosis was 6 weeks (range 
0-200 weeks). The median age at the time of first diagnosis as NPBDI was 15 years 2 
months (range 10 years – 15years 11 months). Figure 2 shows the number of cases by age 
of onset. 
 
Figure 2 about here. 
 
Twenty-six (79%) of the confirmed cases were of white British/Irish ethnic origin, 3 (9%) of 
Black African, 2 (6%) of mixed Black/White Caribbean and 2 (6%) of Asian origins. 
 
Symptom Profile in index episode 
 
Figure 3 about here 
 
Figure 3 shows the symptom profile for the confirmed cases: all met (n=33) the diagnostic 
criteria for NPBDI i.e. had elevated mood. Although, all subjects presented with elevated 
mood; 24 (72%) of the sample also reported significant irritability whilst in the index 
manic/mixed episode. The next most frequent symptoms included disinhibited behaviour 
(88%) and decreased need for sleep (82%). Sixteen cases (48%) were reported to have 
psychotic symptoms which in 14 were mood congruent. 
 
Previous Mood Episodes 
 
Amongst the 33 confirmed cases, 20 cases (60%) had had a previous mood episode which 
was diagnosed by the CCAPs retrospectively after the first time diagnosis of NPBDI: 16 
cases had previously had depressive episodes, 5 cases had had a manic episode, 2 cases 
had had a hypomanic episode and 6 cases had had a mixed episode. Only 13 cases (39%) 
had had no history suggestive of previous mood episodes. The questionnaires were not 
designed to collect data on whether these young people had any clinical contact during 
previous episodes so that data were not available. 
 
Co-morbid Conditions 
 
  10 of 24 
Seventeen (52%) confirmed cases were reported by CCAPs to have had features 
suggestive of a co-morbid condition. The most frequent reported conditions were ASD (n=6), 
ADHD (n=5), Conduct disorder (n=3), substance misuse (n=2), anxiety disorders (n=1) and 
tic disorder (n=1) 
 
Family History 
 
A family history of mental health disorders in first or second degree relatives was present in 
27 (82%) cases. Affective disorders were the most frequently reported condition: a history 
of depressive disorder in first degree relatives (n=12) and second degree relatives (n=3). A 
family history of BD was reported in first degree relatives (n=5) and in second degree 
relatives (n=8). Other reported mental health/neurodevelopmental conditions included ASD: 
first degree relatives (n=2) and second degree relatives (n=2) and ADHD: second degree 
relatives (n=2). Substance use disorders were reported for first degree relatives (n=5), 
anxiety disorder: first degree relatives (n=2) and second degree relative (n=1) and functional 
non-affective psychotic illness: second degree relatives  (n=6). 
 
Management 
 
Thirty-two (97%) of the confirmed cases of NPBDI were receiving psychotropic medication 
as depicted in Figure 4. The most frequent agents used for the psychopharmacological 
management of these cases were atypical antipsychotic agents.  
 
Figure 4 about here 
 
Non-pharmacological management: 89% of young people and 85% of caregivers received 
psycho-education with 71% of young persons and 57% of parents/carers receiving additional 
supportive counselling. Sixteen confirmed cases were admitted to hospital with 5 cases 
requiring the use of appropriate mental health legislation. Of the 16 cases that required 
admission to hospital, 12 had psychotic symptoms. The mean (SD) duration of hospital based 
treatment for the index episode of BD was 11.91 weeks (13.19) (Range 2-52 weeks). The 
mean (SD) of Outpatient treatment duration for the index episode was 30.64 weeks (25.08) 
(Range 2-62 weeks). Table 1 shows the type of health professional, services or agencies who 
provided care for the young person following a diagnosis of NPBDI (n=33). 
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Table 1 about here 
 
Results - One year follow-up 
 
Completed follow-up questionnaires were available for 30 confirmed cases (91%) as shown in 
figure 1. Seventeen (57%) cases were reported to have had a relapse(s) and 10 reported no 
further episodes with data unavailable for 3 cases. The cases that were reported to have had 
a relapse had the following episodes: manic episode (n=1), hypomanic episodes (n=9), 
depressive episodes (n=8) and mixed episodes (n=2) within the one year period of follow up 
in this study. For the management of relapses, 5 cases required voluntary admission to hospital 
(1 requiring detention using mental health legislation) and 11 (65%) were treated as 
outpatients. Of the 17 who reported further episodes, 7 had psychotic symptoms. Fifteen cases 
were given medication for the subsequent episode. Four cases had been discharged back to 
primary care at one year follow-up. At follow up, there was the emergence of further mental 
health disorders: anxiety disorder (n=2), traits of an emerging emotionally unstable personality 
disorder (n=2) and substance use disorder (n=3). 
 
Possible antecedents 
 
CCAPs were asked if the young person had experienced any life stress\event in the year prior 
to the diagnosis of NPBD. For 14 cases no particular life stress were reported. For the 
remaining 19 cases the following antecedents were reported: parental separation (n=3), death 
of a relative/friend (n=3), bullying (n=4), abuse (n=2), hospitalisation of a parent/sibling (n=1), 
break up with a best friend (n=2) and stress about school exams (n=8). 
 
Discussion 
This study provides the first contemporaneous data for the active prospective surveillance 
incidence of the first time diagnosis of NPBDI in the British Isles presenting to CCAPs. There 
were 33 of 151 reported cases that met the analytical case definition for NPBDI. Using these 
data we report an overall incidence of 0.59/100,000 cases in youth under the age of 16 
years. 
Incidence 
The reported minimum incidence for first time diagnosis of NPBDI by consultants in child 
and adolescent psychiatry in this study was 0.59/100 000. Although this method may have 
  12 of 24 
been overly restrictive, the advantage of this method was the contemporaneous 
ascertainment of a cohort that allows the authors to report confidently on a minimum 
incidence of NPBDI in the British Isles. Measuring the incidence of a condition can help 
inform and plan the delivery of healthcare provision especially for the first time presentations 
of the condition under study. Estimating the incidence of PBD using cross sectional 
community based surveys can be difficult as there can often be a significant delay between 
onset of symptoms and diagnosis (43). These issues validate the need to study minimum 
incidence of NPBDI using surveillance epidemiology. As far as we are aware no other data 
exists that we can compare our findings with as most studies that have reported on the 
epidemiology of PBD have reported on prevalence. The only other study that has attempted 
to estimate incidence of BD (BDI and BDII) across the life span was the Dutch cohort study 
(12). It is hard to compare the findings of this surveillance incidence of first time diagnosis 
study with the Dutch study as the age ranges are not similar. Very few cases of NPBDI were 
reported in this study for youth under the age of 13 years replicating the UK clinic-based 
study finding of Chan and colleagues (9). The mean monthly reporting yellow card response 
rate over the 13 month study period was 63%. This response rate was comparable to that 
reported for non-transient childhood conversion disorder study (66.2%) (40) and childhood 
non-affective psychoses study (67%) (41).  
 
It was interesting that in this study only 3 cases were ‘duplicate’ cases (being seen by local 
district and specialist tertiary services). Given the uncommon presentation of PBD, the 
research team had hypothesised that the numbers of cases requiring a specialist second 
opinion would be higher thereby raising the number of duplicate cases. One possible 
explanation could be that as the project was developed to study the incidence of NPBDI, 
these cases were easier to diagnose with confidence within the community and therefore 
did not require a specialist second opinion. 
 
Index episode and follow up 
As would be expected from data from recent publications (11) the majority of cases that met 
the analytical case definition were aged 15 years and over. Interestingly only 9 of the 33 
confirmed cases of NPBDI presented in a mixed episode. None of the subjects met the 
diagnostic criteria for rapid cycling BD over the one year follow up period. Studies often 
report youth with PBD as presenting in mixed, rapid cycling states (44). A potential 
explanation for the lack of these findings was the ascertainment of youth with NPBDI. It is 
possible that the youth with NPBDI in this study have a different course of the disorder 
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compared with youth with PBD presenting in mixed rapid cycling states; however, this 
hypothesis requires further investigation. In keeping with previous literature, many of the 
subjects with NPBDI initially presented with depression prior to their first manic/mixed 
episode (45). Prior to their diagnosis of NPBDI, of the 33 cases, 20 cases had had previous 
mood episodes. Of these, 16 cases had had depressive episodes which highlight the need 
to monitor for conversion to BD in children and adolescents presenting with severe 
depressive episodes and those with a family history of mood disorders although recent data 
suggests that the risk may not be as high as previously thought (46). Only 13 of the 33 cases 
presented with no previous history of mood episodes. However, the small numbers require 
caution to be exercised when interpreting this data. 
 
Co-morbidities and Family History 
Co-morbid mental health disorders are frequently seen in adults with BD with about 65% 
reporting an additional DSM IV Axis I lifetime diagnosis and about one third reporting at least 
one additional current diagnosis (47). The rates of comorbidity in PBD are reported as even 
higher and include co-morbid neurodevelopmental disorders such as ADHD (29, 30) and 
ASD (48). Fifty-two percent of the confirmed cases in this study had features suggestive of 
another co-morbid disorder with the largest group being neurodevelopmental disorders 
(ASD: 6; ADHD; 5). Interestingly only 1 of the cases was reported to have a co-morbid 
anxiety disorder at the time of diagnosis. This figure increased to 3 cases at the point of 1-
year follow-up. This was lower than previously reported (36, 37)which specifically screened 
the study populations for anxiety symptoms from the USA. The significantly higher rate of 
comorbid anxiety symptoms as well as other comorbidities in samples from the USA 
compared to Europe has been previously well described (49). Thus, the rate of comorbid 
anxiety found in this study might be more likely to resemble what can be expected in a 
sample of NPBDI in Europe.  
The rates of mental health disorders in families of youth with PBD has previously been 
reported as elevated (50). In keeping with this published finding, our study reported that 82% 
of the confirmed cases of NPBDI had a family history of neurodevelopmental and/or mental 
health disorders. Studies have reported on differences in the family environment of bipolar 
families compared with healthy control families (51-53). This not only highlights the 
increased vulnerability of youth with a family history of mood disorders to develop NPBDI, 
but also highlights the potential benefit of therapeutic interventions with families to increase 
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the resilience of affected individuals and their carers who often have mental health needs of 
their own (53).  
Management 
The most frequent pharmacological agents used to treat the index episode of NPBDI were 
atypical antipsychotics. This would be in keeping with practice guidelines for the 
management of PBD (33, 54). These guidelines advise caution with reference to the 
potential serious short, medium and long term side effects associated with use of atypical 
antipsychotics including the risks of metabolic syndrome and movement disorders. The 
treatment guidelines advise caution with the use of sodium valproate in females of child 
bearing age given the risk of polycystic ovary syndrome and congenital anomalies (33, 54). 
The results of this study identified that 4 female subjects were receiving treatment with 
Sodium Valproate. The questionnaires were not designed to ask for the reasons prompting 
the choice of a particular psychotropic agent. It is possible (in line with practice guidelines 
(33, 54)) that the reported use of sodium valproate in the 4 young teenagers might have 
been as a consequence of an initial non response to atypical antipsychotics or perhaps a 
need for augmentation with sodium valproate. Only 2 subjects were being prescribed 
Lithium. The majority of youth (89%) and caregivers (85%) received psychoeducation which 
was in keeping with the recommendations of the NICE guidelines (33). It has also been 
reported in the USA that psychotherapies that include psychoeducational components such 
as the Family Focused Treatment for Adolescents with BD reduce the duration of depressive 
episodes (55) and our group is studying the feasibility of adapting this to the UK NHS context 
(56) 
Strengths and Limitations 
As far as the authors are aware this study provides the first data both on the incidence of 
first time diagnosis of NPBDI and the 1-year follow-up of these cases. For rare conditions, 
surveillance epidemiology is a well-established methodology (39-41) and supplements 
information that may be gathered from questionnaire based epidemiology studies (8). An 
added advantage of surveillance epidemiology is that cases are reported by experienced 
clinicians (in this case CCAPs) and the cases are then further validated using stringent 
research criteria. This study not only allowed data  on a minimum incidence of first time 
diagnoses of NPBDI in the British Isles which can inform service provision but also captured 
data on how the cases are currently being managed.  
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Limitations common to studies employing surveillance epidemiology include relying on a 
single information source- i.e. the busy responsible CCAPs to report cases and then 
complete questionnaires. Further, there is evidence in this study that this sampling 
procedure cannot be guaranteed to be comprehensive. The authors were aware that data 
were unavailable for 15 young people due to loss to follow up after initial notification. In 
CAPSS methodology when a CCAP initially notifies a case to CAPSS, no patient identifiable 
information is shared on the yellow card. This means that if the notifying CCAP is then no 
longer in post (for example through retirement or moving post) the study team cannot 
request the new post holder to fill in the initial questionnaire. Other cases may not have been 
identified or received a diagnosis and/or may not have been referred or assessed within 
Child and Adolescent Mental Health Services. It would be of interest to study whether 
approaches such as ‘tailored intensive liaison’ used by Perez and colleagues to improve 
rates of detection of first episode psychosis could also help identify cases of NPBDI (57). 
Further, although the study collected data on medication use at both baseline and follow up, 
data were not obtained on the order in which these medications had been used. The 
questionnaires were developed to capture management strategies without overburdening 
the CCAPs. Lastly, as this was an incidence study, caution must be exercised when 
interpreting co-morbid conditions and family history as these are best captured in studies 
that estimate prevalence. 
 
To conclude, this study provides data confirming that the first time diagnosis of NPBDI by 
CCAPs is infrequent. Given these low rates of diagnosis, further research in the British Isles 
should monitor secular trends in the rates of diagnosis of NPBDI. Finally, the relapse rates 
reported over the follow up period indicate the severity of the disorder and emphasise the 
need for early and accurate diagnosis, careful follow up and the necessity of successful 
transition planning from child and adolescent mental health services to adult mental health 
services. 
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Figure 1. Flow diagram of case ascertainment 
	
Number of cases reported and initial questionnaires sent: 
151 
Number of initial questionnaires returned: 126 (83.44%) 
Number of cases that met restrictive analytical case 
definition for NPBDI: 33 (26.19%)  
Number of follow up questionnaires returned: 30 (90.91%) 
Number of follow up questionnaires sent: 33 
Reasons for and number of cases not meeting the 
restrictive analytical definition: 
 
Age at time of index episode >16 years: 30 cases 
Insufficient symptom duration (<7 days): 16 cases 
CCAP retired and/or moved job: 15 cases 
Pre-existing cases (not new onset in past month): 14 cases 
CCAP revised diagnosis after reporting case: 13 cases 
Duplicate case (case reported by >1 CCAP): 3 cases 
Substance induced episode: 2 cases 
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Figure 2. Number of cases by age at onset 
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Figure 3. % of cases reporting symptom/type of behaviour  
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Figure 4. Type of medication prescribed  
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Table 1. Type of agency/professional involved in the care of NPBDI cases 
 
Child Psychiatrist 33 
Clinical Psychologist 9 
GP 11 
Paediatrician 3 
Adult Psychiatrist 4 
Early Intervention in Psychosis Service 8 
Educational Psychologist 2 
Social Worker 9 
Nurse 13 
Occupational Therapist 4 
Family Therapist 7 
Special Educational Provision 4 
School Counsellor 3 
Non-statutory Agencies 2 
Charity Self-help and/or websites 3 
Other 3 
 
 
 
  
  22 of 24 
Bibliography 
 
 
1. Kraeplin E. Psychiatrie - Ein Lehrbuch für Studierende und Ärzte. 5 edition. Barth, 1896. 
2. Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of 
pediatric bipolar disorder. J Clin Psychiatry. 2011; 72(9): 1250-6. 
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime 
and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the 
National Comorbidity Survey. Arch Gen Psychiatry. 1994; 51: 8-19. 
4. Lewisohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older 
adolescents: prevalence, phenomenology, comorbidity and course. Journal of American Academy 
of Child and Adolescent Psychiatry. 1995; 34: 454-63. 
5. Costello EJ, Angold A, Burns BJ, Stangl DK, Tweed DL, Erkanli A, et al. The Great Smoky 
Mountains Study of Youth: goals, design, methods, and the prevalence of DSM-III-R disorders. 
Arch Gen Psychiatry. 1996; 53: 1129-36. 
6. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-
national epidemiology of major depression and bipolar disorder. The Journal of the American 
Medical Association. 1996; 276: 293-9. 
7. Johnson JG, Cohen P, Brook JS. Associations between bipolar disorder and other 
psychiatric disorders during adolescence and early adulthood: a community-based longitudinal 
investigation. American Journal of Psychiatry. 2000; 157: 1679-81. 
8. Stringaris A, Santosh P, Leibenluft E, Goodman R. Youth meeting symptom and 
impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiry. 
J Child Psychol Psychiatry. 2010; 51(1): 31-8. 
9. Chan J, Stringaris A, Ford T. Bipolar Disorder in Children and Adolescents Recognised in 
the UK: A Clinic-Based Study. Child and adolescent mental health. 2011; 16(2): 71-8. 
10. Goodman R, Simonoff E. Reliability of clinical ratings by trainee child psychiatrists: a 
research note. J Child Psychol Psychiatry. 1991; 32(3): 551-5. 
11. Post RM, Luckenbaugh D, Leverich GS, Altshuler L, Frye MA, Suppes T, et al. Incidence of 
childhood-onset bipolar illness in the USA and Europe. British Journal of Psychiatry. 2008; 192: 
150-1. 
12. Kroon JS, Wohlfarth TD, Dieleman J, Sutterland AL, Storosum JG, Denys D, et al. 
Incidence rates and risk factors of bipolar disorder in the general population: a population-based 
cohort study. Bipolar Disord. 2013; 15(3): 306-13. 
13. Van Meter AR, Burke C, Kowatch RA, Findling RL, Youngstrom EA. Ten-year updated 
meta-analysis of the clinical characteristics of pediatric mania and hypomania. Bipolar Disord. 
2016; 18(1): 19-32. 
14. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical phenotypes 
of juvenile mania. Am J Psychiatry. 2003; 160(3): 430-7. 
15. Biederman J, Faraone S, Mick E, Wozniak J, Chen L, Ouellette C, et al. Attention-deficit 
hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc 
Psychiatry. 1996; 35(8): 997-1008. 
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders- 
Fourth Edition. American Psychiatric Association, 1994. 
17. Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of 
bipolar disorder in youths. Am J Psychiatry. 2011; 168(2): 129-42. 
18. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime 
prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey 
Replication--Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010; 49(10): 
980-9. 
19. Papolos D, Mattis S, Golshan S, Molay F. Fear of harm, a possible phenotype of pediatric 
bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes. J 
Affect Disord. 2009; 118(1-3): 28-38. 
20. Youngstrom EA, Birmaher B, Findling RL. Pediatric bipolar disorder: validity, 
phenomenology, and recommendations for diagnosis. Bipolar Disord. 2008; 10(1 Pt 2): 194-214. 
  23 of 24 
21. Luby JL, Mrakotsky C, Heffelfinger A, Brown K, Hessler M, Spitznagel E. Modification of 
DSM-IV criteria for depressed preschool children. Am J Psychiatry. 2003; 160(6): 1169-72. 
22. Mick E, Spencer T, Wozniak J, Biederman J. Heterogeneity of irritability in attention-
deficit/hyperactivity disorder subjects with and without mood disorders. Biol Psychiatry. 2005; 
58(7): 576-82. 
23. Wozniak J, Biederman J, Kwon A, Mick E, Faraone S, Orlovsky K, et al. How cardinal are 
cardinal symptoms in pediatric bipolar disorder? An examination of clinical correlates. Biol 
Psychiatry. 2005; 58(7): 583-8. 
24. Axelson D, Birmaher B, Strober M, Gill MK, Valeri S, Chiappetta L, et al. Phenomenology of 
children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006; 63(10): 
1139-48. 
25. Findling RL, Gracious BL, McNamara NK, Youngstrom EA, Demeter CA, Branicky LA, et al. 
Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar 
Disord. 2001; 3(4): 202-10. 
26. Geller B, Zimmerman B, Williams M, DelBello MP, Frazier J, Beringer L. Phenomenology of 
prepubertal and early adolescent bipolar disorder: examples of elated mood, grandiose 
behaviours, decreased need for sleep, racing thoughts and hypersexuality. J Child Adolesc 
Psychopharmacol. 2002; 12(1): 3-9. 
27. Youngstrom EA, Freeman AJ, Jenkins MM. The assessment of children and adolescents 
with bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009; 18(2): 353-90, viii-ix. 
28. Carlson GA, Meyer SE. Phenomenology and diagnosis of bipolar disorder in children, 
adolescents, and adults: complexities and developmental issues. Dev Psychopathol. 2006; 18(4): 
939-69. 
29. Galanter CA, Leibenluft E. Frontiers between attention deficit hyperactivity disorder and 
bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2008; 17(2): 325-46, viii-ix. 
30. Youngstrom EA, Arnold LE, Frazier TW. Bipolar and ADHD Comorbidity: Both Artifact and 
Outgrowth of Shared Mechanisms. Clin Psychol (New York). 2010; 17(4): 350-9. 
31. Biederman J, Klein RG, Pine DS, Klein DF. Resolved: mania is mistaken for ADHD in 
prepubertal children. J Am Acad Child Adolesc Psychiatry. 1998; 37(10): 1091-6; discussion 6-9. 
32. Tillman R, Geller B. Controlled study of switching from attention-deficit/hyperactivity 
disorder to a prepubertal and early adolescent bipolar I disorder phenotype during 6-year 
prospective follow-up: rate, risk, and predictors. Dev Psychopathol. 2006; 18(4): 1037-53. 
33. NICE. The management of bipolar disorder in adults, children and adolescents, in primary 
and secondary care. National Institute for Health and Clinical Excellence, 2006. 
34. Birmaher B, Axelson D, Strober M, Gill MK, Valeri S, Chiappetta L, et al. Clinical course of 
children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006; 63(2): 175-
83. 
35. Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, et al. 
Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. 
Biol Psychiatry. 2006; 60(9): 991-7. 
36. Dickstein DP, Rich BA, Binstock AB, Pradella AG, Towbin K, Pine DS, et al. Comorbid 
anxiety in phenotypes of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2005; 15(4): 
534-48. 
37. Jolin EM, Weller EB, Weller RA. Anxiety symptoms and syndromes in bipolar children and 
adolescents. Curr Psychiatry Rep. 2008; 10(2): 123-9. 
38. Sala R, Axelson DA, Castro-Fornieles J, Goldstein T, Ha W, Liao F, et al. Comorbid anxiety 
in children and adolescents with bipolar spectrum disorders: prevalence and clinical correlates. 
Journal of Clinical Psychiatry. 2010; 71(10): 1344-50. 
39. Nicholls DE, Lynn R, Viner RM. Childhood eating disorders: British national surveillance 
study. Br J Psychiatry. 2011; 198(4): 295-301. 
40. Ani C, Reading R, Lynn R, Forlee S, Garralda E. Incidence and 12-month outcome of non-
transient childhood conversion disorder in the U.K. and Ireland. Br J Psychiatry. 2013; 202: 413-8. 
41. Tiffin PA, Kitchen CE. Incidence and 12-month outcome of childhood non-affective 
psychoses: British national surveillance study. Br J Psychiatry. 2015; 206(6): 517-8. 
42. NICE. Bipolar Disorder: the assessment and management of bipolar disorder in adults, 
children and young people in primary and secondary care. National Institute for Health and Clinical 
Excellence, 2014. 
  24 of 24 
43. Mantere O, Suominen K, Leppamaki S, Valtonen H, Arvilommi P, Isometsa E. The clinical 
characteristics of DSM-IV bipolar I and II disorders: baseline findings from the Jorvi Bipolar Study 
(JoBS). Bipolar Disord. 2004; 6(5): 395-405. 
44. Birmaher B. Bipolar disorder in children and adolescents. Child and adolescent mental 
health. 2013; 18(3). 
45. Suominen K, Mantere O, Valtonen H, Arvilommi P, Leppamaki S, Paunio T, et al. Early age 
at onset of bipolar disorder is associated with more severe clinical features but delayed treatment 
seeking. Bipolar Disord. 2007; 9(7): 698-705. 
46. Pfennig A, Ritter PS, Höfler M, Lieb R, Bauer M, Wittchen HU, et al. Symptom 
characteristics of depressive episodes prior to the onset of mania or hypomania. Acta Psychiatr 
Scand. 2016; 133(3): 196-204. 
47. McElroy SL, Altshuler LL, Suppes T, Keck PE, Jr., Frye MA, Denicoff KD, et al. Axis I 
psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar 
disorder. Am J Psychiatry. 2001; 158(3): 420-6. 
48. Joshi G, Biederman J, Petty C, Goldin RL, Furtak SL, Wozniak J. Examining the 
comorbidity of bipolar disorder and autism spectrum disorders: a large controlled analysis of 
phenotypic and familial correlates in a referred population of youth with bipolar I disorder with and 
without autism spectrum disorders. J Clin Psychiatry. 2013; 74(6): 578-86. 
49. Post RM, Altshuler L, Kupka R, McElroy S, Frye MA, Rowe M, et al. More pernicious 
course of bipolar disorder in the United States than in many European countries: implications for 
policy and treatment. J Affect Disord. 2014; 160: 27-33. 
50. Rende R, Birmaher B, Axelson D, Strober M, Gill MK, Valeri S, et al. Childhood-onset 
bipolar disorder: Evidence for increased familial loading of psychiatric illness. J Am Acad Child 
Adolesc Psychiatry. 2007; 46(2): 197-204. 
51. Chang KD, Blasey C, Ketter TA, Steiner H. Family environment of children and adolescents 
with bipolar parents. Bipolar Disord. 2001; 3(2): 73-8. 
52. Romero S, Delbello MP, Soutullo CA, Stanford K, Strakowski SM. Family environment in 
families with versus families without parental bipolar disorder: a preliminary comparison study. 
Bipolar Disord. 2005; 7(6): 617-22. 
53. Barron E, Sharma A, Le Couteur J, Rushton S, Close A, Kelly T, et al. Family environment 
of bipolar families: a UK study. J Affect Disord. 2014; 522: 152-4. 
54. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment 
of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007; 
46(1): 107-25. 
55. Miklowitz DJ, Axelson DA, Birmaher B, George EL, Taylor DO, Schneck CD, et al. Family-
focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. Arch 
Gen Psychiatry. 2008; 65(9): 1053-61. 
56. Neely J, Miklowitz D, Le Couteur A, Ryan V, Vale L, McGovern R, et al. A feasibility study 
of a Family Focused Treatment for Adolescents with Bipolar Disorder—the FAB study. Pilot and 
Feasibility Studies. 2015; 1(1): 1-9. 
57. Perez J, Jin H, Russo DA, Stochl J, Painter M, Shelley G, et al. Clinical effectiveness and 
cost-effectiveness of tailored intensive liaison between primary and secondary care to identify 
individuals at risk of a first psychotic illness (the LEGs study): a cluster-randomised controlled trial. 
Lancet Psychiatry. 2015; 2(11): 984-93. 
